GlucoTrack Inc
GCTK
查看详细走势图
4.490USD
-0.010-0.22%
收盘 12/24, 13:00（美东）报价延迟15分钟
4.04M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-0.22%
5天
-5.27%
1月
-6.46%
6月
-27.70%
今年开始到现在
-99.00%
1年
-98.55%
查看详细走势图
TradingKey GlucoTrack Inc股票评分
单位: USD 更新时间: 2025-12-24操作建议
GlucoTrack Inc当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名242/404位。机构持股占比很高，中期看，股价处于下降通道。近一个月，市场表现非常差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
GlucoTrack Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
0
位分析师
--
评级
0.000
目标均价
0.00%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
GlucoTrack Inc亮点
亮点风险
Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
GlucoTrack Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
GlucoTrack Inc简介
Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
公司代码GCTK
公司GlucoTrack Inc
CEOGoode (Paul V)
网址https://glucotrack.com/
常见问题
GlucoTrack Inc(GCTK)的当前股价是多少？
GlucoTrack Inc(GCTK)的当前股价是 4.490。
GlucoTrack Inc的股票代码是什么？
GlucoTrack Inc的股票代码是GCTK。
GlucoTrack Inc股票的52周最高点是多少？
GlucoTrack Inc股票的52周最高点是468.000。
GlucoTrack Inc股票的52周最低点是多少？
GlucoTrack Inc股票的52周最低点是4.220。
GlucoTrack Inc的市值是多少？
GlucoTrack Inc的市值是4.04M。
GlucoTrack Inc的净利润是多少？
GlucoTrack Inc的净利润为-22.60M。
现在GlucoTrack Inc(GCTK)的股票是买入、持有还是卖出？
根据分析师评级，GlucoTrack Inc(GCTK)的总体评级为--，目标价格为--。
GlucoTrack Inc(GCTK)股票的每股收益（EPS TTM）是多少
GlucoTrack Inc(GCTK)股票的每股收益（EPS TTM）是-1335.127。
相关品种
